Table 1.
ERQC/ERAD components and association of their expression levels with cancer patient survival in the Human Protein Atlas (HPA) [24, 25].
| Protein/gene and UniProt entry/name | Prognosis upon overexpression (Human Protein Atlas, p < 0.001) | Frequency of somatic mutations in cancer (COSMIC) |
|---|---|---|
| GCS1/MOGS, Q13724/MOGS_HUMAN | Unfavourable prognosis in renal, liver, and colorectal cancers | 191/47211 (0.4%) |
| ER αGlu II α subunit/GANAB, Q14697/GANAB_HUMAN | Unfavourable prognosis in liver and urothelial cancers | 254/47211 (0.5%) |
| ER αGlu II β subunit/PRKCSH, P14314/GLU2B_HUMAN | Unfavourable prognosis in renal cancer | 191/47211 (0.4%) |
| UGGT1/UGGT1, Q9NYU2/UGGG1_HUMAN | Unfavourable prognosis in renal cancer | 333/47297 (0.7%) |
| UGGT2/UGGT2, Q9NYU1/UGGG2_HUMAN | Unfavourable prognosis in lung and liver cancers | 406/47212 (0.8%) |
| Sep15/Sep15, O60613/SEP15_HUMAN | Unfavourable prognosis in liver, head, and neck cancers but favourable prognosis in colorectal cancer | 17/47187 (0.04%)) |
| Calnexin/CANX, P27824/CALX_HUMAN | Favourable prognosis in colorectal cancer but unfavourable in thyroid cancer | 151/47211 (0.3%) |
| Calreticulin/CALR, P27797/CALR_HUMAN | Favourable prognosis in ovarian cancer but unfavourable in renal cancer | 4344/81169 (5.3%) |
| ER UDPase, O75356, ENTP5_HUMAN | Favourable prognosis in renal cancer | 110/47209 (0.2%) |
| ER αMan I, Q9UKM7, MA1B1_HUMAN | Unfavourable prognosis in liver cancer | 178/47354 (0.4%) |
| EDEM1, Q92611, EDEM1_HUMAN | N/A | 141/47255 (0.3%) |
| EDEM2, Q9BV94 EDEM2_HUMAN | Unfavourable prognosis in renal cancer | 162/35626 (0.4%) |
| EDEM3, Q9BZQ6 EDEM3_HUMAN | Unfavourable prognosis in renal cancer | 231/35629 (0.6%) |
| ERDJ5, Q8IXB1, DJC10_HUMAN | Favourable prognosis in endometrial cancer but unfavourable in renal and thyroid cancers | 205/47347 (0.4%) |
| HRD1, Q86TM6, SYVN1_HUMAN | Favourable prognosis in head and neck cancer | 143/47298 (0.3%) |
| OS-9/, Q13438/OS9_HUMAN | N/A | 188/47797 (0.4%) |
The HPA correlation (p < 0.001) between high levels of expression of the protein with the survival rates of cancer patients is reported, together with the frequency of somatic mutations detected in the same genes, as per the Catalogue of Somatic Mutations in Cancer (COSMIC) [27]. For comparison, the tumour suppressors TP53 and CDKN2A have mutation frequencies of 25% (40416/160297) and 6% (6067/100370), respectively.